Get Started
Companies › NUVL

Nuvalent

NUVL · NASDAQ
Mid ClinicalMixed

Nuvalent is developing next-generation kinase inhibitors designed to overcome the key limitations of approved ROS1 and ALK TKIs - resistance mutations, CNS penetration, and TRK-related toxicity. With zidesamtinib's PDUFA date of September 18, 2026 and neladalkib NDA submission planned for 1H 2026, the company has two potential near-term commercial assets in validated oncology markets.

Market Cap
$7.3B
Cash Runway
Into 2029
Pipeline
3 Assets
Priority
High
Investment Thesis

Bull Case

  • Zidesamtinib and neladalkib TRK-sparing design addresses major safety limitation of competitors
  • Exceptional durability data: 93% DOR ≥18 months for zidesamtinib 1 prior TKI; 60% DOR ≥18 months for neladalkib TKI pre-treated
  • Dual programs de-risk company - success in either ROS1 or ALK creates substantial value
  • Strong CNS activity addresses critical unmet need (50%+ of patients develop brain mets)
  • Clean safety profile with low discontinuation rates (2% zidesamtinib, 5% neladalkib)

Bear Case

  • Repotrectinib and taletrectinib already approved with established market presence in ROS1
  • Lorlatinib 1L data (mPFS not reached at 60 months) sets high bar for ALK
  • Commercial execution risk for a first-time launch organization
  • NVL-330 HER2 program still early (Phase 1) with significant competition

Pipeline

Asset Target Stage Lead Indication Next Catalyst
neladalkib ALK Phase 2 ALK+ NSCLC (TKI pre-treated) NDA submission (1H 2026)
NVL-330 HER2 Phase 1 HER2+ NSCLC Phase 1 dose escalation data (2026-2027)
zidesamtinib ROS1 NDA Filed ROS1+ NSCLC (TKI pre-treated) PDUFA target action date (September 18, 2026)
Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy